- Home
- AVK vs AVIR Comparison
AVK vs AVIR Comparison
Compare AVK & AVIR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | AVK | AVIR |
|---|---|---|
| Founded | N/A | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Medicinal Chemicals and Botanical Products |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 513.0M | 429.1M |
| IPO Year | 2003 | 2020 |
Fundamental Metrics
Financial Performance| Metric | AVK | AVIR |
|---|---|---|
| Price | $11.52 | $5.16 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $9.42 |
| AVG Volume (30 Days) | 186.1K | ★ 273.8K |
| Earning Date | 01-01-0001 | 11-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 3.00 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $351,367,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.77 | $2.87 |
| 52 Week High | $13.28 | $6.45 |
Technical Indicators
Market Signals| Indicator | AVK | AVIR |
|---|---|---|
| Relative Strength Index (RSI) | 36.83 | 49.11 |
| Support Level | $10.77 | $5.01 |
| Resistance Level | $13.01 | $5.76 |
| Average True Range (ATR) | 0.16 | 0.22 |
| MACD | 0.00 | -0.02 |
| Stochastic Oscillator | 22.77 | 38.93 |
Price Performance
Historical ComparisonAbout AVK Advent Convertible and Income Fund
Advent Convertible & Income Fund is a diversified, closed-end management investment company. The fund's investment objective is to provide total return through a combination of capital appreciation and current income. The Fund invests in various sectors, such as communications, utilities, energy, industrial, technology, and others.
About AVIR Atea Pharmaceuticals Inc.
Atea Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company focused on the discovery, development, and commercialization of oral antiviral therapies for serious viral diseases. The company's pipeline includes a regimen of bemnifosbuvir and ruzasvir for the treatment of hepatitis C virus (HCV) infection and AT-587 for the treatment of hepatitis E virus (HEV) infection.